The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Joel W. Neal
Research Funding - Genentech
Nathan A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim; Oncogenex
Research Funding - Genentech
Ramaswamy Govindan
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Pfizer
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Pfizer
Research Funding - Genentech
Michael Lanuti
Consultant or Advisory Role - Boston Scientific
Rachel Pam Greenerger Rosovsky
No relevant relationships to disclose
Rebecca Suk Heist
No relevant relationships to disclose
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Pfizer
Honoraria - Novartis
Research Funding - AstraZeneca; Novartis
Jennifer S. Temel
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Pasi A. Janne
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals; Roche
Other Remuneration - LabCorp
Thomas James Lynch
Employment or Leadership Position - Infinity
Consultant or Advisory Role - Astex Therapeutics; Boehringer Ingelheim; Merck
Stock Ownership - Infinity
Honoraria - Astex Therapeutics; Boehringer Ingelheim; Merck
Other Remuneration - Partners Healthcare
Christopher G. Azzoli
Research Funding - Genentech
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
Research Funding - Genentech